Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH5CAQ)

Drug Name

4-(2-amino-1,3-thiazol-4-yl)phenol Drug Info

Synonyms

4-(2-Amino-1,3-thiazol-4-yl)phenol; 57634-55-6; 4-(2-amino-4-thiazolyl)phenol; 4-(2-Amino-thiazol-4-yl)-phenol; 4-(2-aminothiazol-4-yl)phenol; CHEMBL483790; QGSJYYIRAFRPIT-UHFFFAOYSA-N; Phenol, 4-(2-amino-4-thiazolyl)-; 2-amino-4-(4-hydroxyphenyl)-thiazole; NSC405294; 3fu3; Oprea1_415030; SCHEMBL5321407; p-(2-Amino-4-thiazolyl)phenol; CTK5A7198; DTXSID30323956; MolPort-000-141-769; HMS3604B06; Phenol,4-(2-amino-4-thiazolyl)-; AC1L8637; KS-00000A4L; ZINC16951624; STK723345; SBB018017; BDBM50293592; KM0129; 5926AE; 4-(2-Aminothiazol-4-yl)phenol

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 346926
CAS Number: CAS 57634-55-6
TTD Drug ID: DMH5CAQ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Leukotriene A-4 hydrolase (LTA4H)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bestatin	DM8L9D4	Acute myeloid leukaemia	2A60	Approved	[3]
LYS006	DMI17QR	Ulcerative colitis	DD71	Phase 2	[4]
Acebilustat	DM19UTO	Chronic blistering skin disorder	ME63.3	Phase 1	[5]
DG051	DM3I0GS	Myocardial infarction	BA41-BA43	Discontinued in Phase 2	[6]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[7]
JNJ-10392980	DMZH0K8	Discovery agent	N.A.	Investigative	[8]
2-(4-phenoxyphenoxy)ethanamine	DM7TBUJ	Discovery agent	N.A.	Investigative	[9]
3-(Benzyloxy)Pyridin-2-Amine	DM35VEI	Discovery agent	N.A.	Investigative	[7]
2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine	DMD2QVO	Discovery agent	N.A.	Investigative	[10]
2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole	DMMYJ3R	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Fructose-1,6-bisphosphatase (FBP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Managlinat dialanetil	DMBYDNE	Type-2 diabetes	5A11	Phase 2	[11]
MB07803	DMHU8SJ	Type-2 diabetes	5A11	Phase 2	[12]
4,6-Dichloro-1H-indole-2-carboxylic acid	DM62XC3	Discovery agent	N.A.	Investigative	[1]
Fructose-6-Phosphate	DMU5SAF	Discovery agent	N.A.	Investigative	[7]
1-(4-aminophenylsulfonyl)-3-(2-mercaptoethyl)urea	DM4G0NH	Discovery agent	N.A.	Investigative	[13]
2,5-Anhydroglucitol-1,6-Biphosphate	DMLDHMB	Discovery agent	N.A.	Investigative	[7]
1-(2-mercaptoethyl)-3-(m-tolylsulfonyl)urea	DMIPAMW	Discovery agent	N.A.	Investigative	[13]
4-(4-(4-Nitrophenyl)thiazol-2-ylamino)phenol	DMA9TCD	Discovery agent	N.A.	Investigative	[2]
3-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol	DM8EH07	Discovery agent	N.A.	Investigative	[2]
2-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol	DMOYT8I	Discovery agent	N.A.	Investigative	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fructose-1,6-bisphosphatase (FBP)	TTWHDVK	F16P1_HUMAN; F16P2_HUMAN	Inhibitor	[2]
Leukotriene A-4 hydrolase (LTA4H)	TTXZEAJ	LKHA4_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2	A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase. Bioorg Med Chem. 2009 Jun 1;17(11):3916-22.
3	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
4	Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A(4) Hydrolase. J Med Chem. 2021 Feb 25;64(4):1889-1903.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
7	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
9	Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52.
10	Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8.
11	MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci U S A. 2005 May 31;102(22):7970-5.
12	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
13	Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4708-12.